An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Saved in:
| Title: | An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. |
|---|---|
| Authors: | Bible KC; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Menefee ME; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Lin CJ; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Millward MJ; Department of Medical Oncology, University of Western Australia, Perth, Australia., Maples WJ; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Goh BC; Division of Medical Oncology, National University Cancer Institute, Singapore, Singapore., Karlin NJ; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA., Kane MA; Department of Medical Oncology, University of Colorado, Denver, Colorado, USA., Adkins DR; Division of Medical Oncology, Department of Medicine, Washington University, St. Louis, Missouri, USA., Molina JR; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Donehower RC; Division of Medical Oncology, Department of Medicine, Johns Hopkins, Baltimore, Maryland, USA., Lim WT; Division of Medical Oncology, National University Cancer Institute, Singapore, Singapore., Flynn PJ; Minnesota Oncology, Minneapolis, Minnesota, USA., Richardson RL; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Traynor AM; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA., Rubin J; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., LoRusso PM; Department of Oncology, Wayne State University, Detroit, Michigan, USA., Smallridge RC; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA., Burton JK; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Suman VJ; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kumar A; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Voss JS; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Rumilla KM; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kipp BR; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Chintakuntlawar AV; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Harris P; Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland, USA., Erlichman C; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA. |
| Source: | Thyroid : official journal of the American Thyroid Association [Thyroid] 2020 Sep; Vol. 30 (9), pp. 1254-1262. Date of Electronic Publication: 2020 Jul 29. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1557-9077 |
|---|---|
| DOI: | 10.1089/thy.2019.0269 |
